
Andrea Corona
Senior Editor at Pharma Manufacturing
Currently: Sr. Editor @PharmaMfg Previously: Associate Editor @biocompare & Digital @scifri
Articles
-
1 month ago |
pharmamanufacturing.com | Andrea Corona
Gilead Sciences has announced a multi-year, multi-billion-dollar investment plan designed to strengthen its U.S.-based manufacturing and research infrastructure. The initiative includes $11 billion in new capital and operational expenditures, building on a previously announced $21 billion spend through 2030. Combined, the company projects these efforts will generate $43 billion in economic impact over the next five years.
-
1 month ago |
pharmamanufacturing.com | Andrea Corona
Bristol Myers Squibb has announced plans to invest $40 billion in the United States over the next five years, focusing on expanding its domestic research, development, and manufacturing capabilities. The investment will be directed toward advancing U.S.-based research and development, building out domestic manufacturing infrastructure, and incorporating emerging technologies such as artificial intelligence and machine learning to accelerate drug discovery and development.
-
1 month ago |
pharmamanufacturing.com | Andrea Corona
Bristol Myers Squibb has announced plans to invest $40 billion in the United States over the next five years, focusing on expanding its domestic research, development, and manufacturing capabilities. The investment will be directed toward advancing U.S.-based research and development, building out domestic manufacturing infrastructure, and incorporating emerging technologies such as artificial intelligence and machine learning to accelerate drug discovery and development.
-
1 month ago |
pharmamanufacturing.com | Andrea Corona
Amid looming tariff threats and a war cry by President Donald Trump to return manufacturing to the United States, the FDA continues to face persistent challenges overseeing foreign drug manufacturing, particularly in China and India. While the agency has ramped up post-pandemic inspections and introduced new tools such as unannounced visits, its ability to consistently monitor global supply chains remains limited by staffing gaps and oversight inconsistencies.
-
2 months ago |
pharmamanufacturing.com | Andrea Corona
Sterile injectable drugs account for over 40% of new drug approvals, but their production remains slow, costly, and heavily regulated.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 72
- Tweets
- 267
- DMs Open
- No

RT @cbquist: why do the fall and winter seasons have their own ubiquitous flavors (pumpkin spice, peppermint/gingerbread) but spring and su…

RT @PharmaMfg: 𝟐𝟎 𝐘𝐄𝐀𝐑𝐒 𝐨𝐟 @𝐏𝐡𝐚𝐫𝐦𝐚𝐌𝐟𝐠: As part of our anniversary celebration, #equipment/#services suppliers that have been in the pharma…

RT @PharmaMfg: Within pharma, there’s a new promise on the horizon: a world without disease made possible through #cell and #gene therapies…